naproxcinod Articles
NicOx says it is “well funded” and has robust pipeline, despite recent disappointment with naproxcinod
20 May 2010
Disappointments for NicOx, as FDA panel rejects naproxcinod, and GlaxoSmithKline, which halts Promacta trial
13 May 2010
Showing 1-2 of 2 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
